论文部分内容阅读
目的:分析急性心肌梗死患者行重组组织型纤溶酶原激活剂(r-tp A)与尿激酶静脉溶栓治疗对疗效及安全性的影响。方法:选取本院2013年12月-2015年12月收治的急性心肌梗死98例患者临床资料进行回顾性分析,根据治疗所用不同方案分成两组,将行尿激酶静脉溶栓治疗42例患者设为对照组,将行r-tp A静脉溶栓治疗56例患者设为观察组,对两组疗效指标、血管再通率与安全性进行对比分析。结果:观察组在两组治疗后疗效指标(MYO、CK-MB、NT-pro BNP)均改善基础上,其改善幅度更显著(P<0.05);观察组各时间段血管再通率均比对照组高,且心血管总不良事件率比对照组显著降低(10.71%vs 57.14%,P<0.05)。结论:急性心肌梗死患者行r-tp A静脉溶栓治疗能够优化各项疗效指标,提高血管再通率,并减少心血管不良事件发生,可应用于临床。
Objective: To analyze the effect and safety of recombinant tissue-type plasminogen activator (r-tp A) and urokinase intravenous thrombolysis in patients with acute myocardial infarction. Methods: The clinical data of 98 patients with acute myocardial infarction admitted from December 2013 to December 2015 in our hospital were retrospectively analyzed. According to the different schemes used in the treatment, the patients were divided into two groups. Thrombolytic therapy with urokinase in 42 patients As control group, 56 patients treated with intravenous thrombolysis of r-tp A were selected as the observation group, and the curative effect, recanalization rate and safety of the two groups were compared. Results: The improvement rate of the observation group was more significant (P <0.05) on the basis of improvement of the curative effect index (MYO, CK-MB, NT-pro BNP) in both groups after treatment; The control group was high and the rate of cardiovascular adverse events was significantly lower than that of the control group (10.71% vs 57.14%, P <0.05). Conclusion: The r-tp A intravenous thrombolysis in patients with acute myocardial infarction can optimize various curative indexes, improve the recanalization rate and reduce the occurrence of cardiovascular adverse events, and can be used in clinic.